SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Senesco Technologies, Inc.’s Lead Therapeutic Candidate, SNS01-T, Granted Orphan Drug Status From FDA for Treatment of Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma